What do the CD20 and PD-L1 biomarker results mean in the context of my follicular lymphoma diagnosis

Based on the NCCN Guidelines provided, I can explain CD20 testing, but I don't see specific information about PD-L1 testing in follicular lymphoma in these sources.

For CD20: According to the NCCN Guidelines for Patients: Follicular Lymphoma, CD20 is one of the key biomarkers tested during immunophenotyping. The guidelines indicate that follicular lymphoma cells are typically "CD20+" (CD20-positive). Specifically, the guidelines state that "FL immunophenotype is usually CD10+, BCL2+, CD23+/-, CD43-, CD5-, CD20+, and BCL6+" (page 17).

CD20 positivity is important because:

1. It helps confirm the diagnosis of follicular lymphoma
2. It helps distinguish FL from other types of lymphoma
3. It may help guide treatment decisions, since some therapies target CD20-positive cells

I cannot make specific claims about PD-L1 testing in follicular lymphoma as this is not covered in the provided guideline sources. I recommend discussing the significance of your specific biomarker results with your oncologist, who can explain how they impact your individual treatment plan.

Would you like me to explain more about other biomarker testing that is typically done for follicular lymphoma according to these guidelines?